belumosudil
belumosudil is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Rezurock. Available dosage form: tablet.
Drug details
- Generic Name
- belumosudil
- Brand Names
- Rezurock
- Application Number
- NDA214783
- Sponsor
- Sanofi S.R.L.
- NDC Codes
- 2
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- BELUMOSUDIL
Indications and Usage
1 INDICATIONS AND USAGE REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. ( 1 )